Retinal disease biotech building antibody biopolymer conjugates and imaging hardware
Kodiak Sciences develops investigational retinal medicines built on its antibody-chemistry conjugate platform. Its stack goes well beyond clinical tooling: alongside Medidata Rave, Veeva and SAS sit FPGAs, Verilog, Zemax and LiDAR, and current senior engineering hiring centers on a hardware and software foundation for a VETi platform, including confocal laser scanning OCT subsystems, pointing to an in-house ophthalmic imaging device effort.
Kodiak Sciences is a public, precommercial biopharmaceutical company headquartered in Palo Alto, California, founded in 2009 with 51–200 employees. It focuses on therapeutics for high-prevalence retinal vascular and inflammatory diseases. Its pipeline includes tarcocimab, an anti-VEGF antibody biopolymer conjugate, plus KSI-501 and KSI-101, bispecific candidates targeting IL-6 and VEGF. The company's discovery work runs on its ABC Platform, which combines antibody-based and chemistry-based approaches, and hiring is concentrated in the United States.
Kodiak uses clinical data tools like Medidata Rave, Oracle Clinical, Veeva, CDISC and SAS, lab tools like LC-MS and HPLC, plus hardware and ML tooling including FPGAs, Verilog, Zemax, PyTorch and TensorFlow, on AWS and Azure.
Yes. Current openings are senior engineering roles in the United States, focused on electronics, software, signal processing and motion-control work for its VETi platform.
Beyond its retinal drug candidates, Kodiak is building VETi platform electronics and software, real-time signal-processing pipelines, motion-control hardware and confocal laser scanning OCT subsystems.
Other companies in the same industry, closest in size
Kodiak Sciences's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.